These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 12618500)

  • 21. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.
    Myers E; Fleming FJ; Crotty TB; Kelly G; McDermott EW; O'higgins NJ; Hill AD; Young LS
    Br J Cancer; 2004 Nov; 91(9):1687-93. PubMed ID: 15477868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
    Osborne CK; Schiff R
    Breast; 2003 Dec; 12(6):362-7. PubMed ID: 14659106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
    van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
    J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
    Fleming FJ; Myers E; Kelly G; Crotty TB; McDermott EW; O'Higgins NJ; Hill AD; Young LS
    J Clin Pathol; 2004 Oct; 57(10):1069-74. PubMed ID: 15452162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
    Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
    Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
    Wong LJ; Dai P; Lu JF; Lou MA; Clarke R; Nazarov V
    BMC Cancer; 2006 May; 6():111. PubMed ID: 16670003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
    Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
    Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
    L H Weischenfeldt K; Kirkegaard T; Rasmussen BB; Giobbie-Hurder A; Jensen MB; Ejlertsen B; Lykkesfeldt AE
    Acta Oncol; 2017 Sep; 56(9):1161-1167. PubMed ID: 28488912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
    Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
    Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
    Oh AS; Lahusen JT; Chien CD; Fereshteh MP; Zhang X; Dakshanamurthy S; Xu J; Kagan BL; Wellstein A; Riegel AT
    Mol Cell Biol; 2008 Nov; 28(21):6580-93. PubMed ID: 18765637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
    Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
    Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
    J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.
    Lahusen T; Fereshteh M; Oh A; Wellstein A; Riegel AT
    Cancer Res; 2007 Aug; 67(15):7256-65. PubMed ID: 17671194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Oh JH; Lee JY; Kim KH; Kim CY; Jeong DS; Cho Y; Nam KT; Kim MH
    Cancer Lett; 2020 Dec; 495():145-155. PubMed ID: 32987137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
    Gago FE; Fanelli MA; Ciocca DR
    J Steroid Biochem Mol Biol; 2006 Jan; 98(1):36-40. PubMed ID: 16188438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.
    Fereshteh MP; Tilli MT; Kim SE; Xu J; O'Malley BW; Wellstein A; Furth PA; Riegel AT
    Cancer Res; 2008 May; 68(10):3697-706. PubMed ID: 18483252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.